Gender differences in autoimmunity associated with exposure to environmental factors

Journal of Autoimmunity

Volumn 38, Issue 2-3, 2012, Pages

  Pollard, K Michael ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Animal; Autoimmunity; Environment; Gender; Human

Indexed keywords

1,1,1 TRICHLORO 2 (2 CHLOROPHENYL) 2 (4 CHLOROPHENYL)ETHANE; 2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; ALDRIN; ASBESTOS; BROMOXYNIL; CARBAMIC ACID; CHLORDANE; CHLORDECONE; COSMETIC; DIELDRIN; ENDRIN; GLIADIN; GLUTENIN; HAIR DYE; HEPTACHLOR; HORDEIN; HYDRALAZINE; LINDANE; MERCURY; METHOXYCHLOR; ORGANIC SOLVENT; PHENOXYACETIC ACID; PRISTANE; PROCAINAMIDE; PROLAMIN; PYRETHROID; SILICON DIOXIDE; TRICHLOROETHYLENE; TRYPTOPHAN;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; BARLEY; CALORIC RESTRICTION; CELIAC DISEASE; DIET; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EOSINOPHILIA MYALGIA SYNDROME; EPSTEIN BARR VIRUS INFECTION; GENDER; GENDER BIAS; GRAVES DISEASE; HUMAN; IDIOPATHIC DISEASE; INNATE IMMUNITY; IONIZING RADIATION; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; MULTIPLE SCLEROSIS; NONHUMAN; OCCUPATIONAL EXPOSURE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RYE; SCLERODERMA; SEX CHROMOSOME; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; THEILERIOSIS; TOXIC OIL SYNDROME; ULTRAVIOLET A RADIATION;

EID: 84858751926     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2011.11.007     Document Type: Review

References (165)

1. Hahn B.H. Targeted therapies in systemic lupus erythematosus: successes, failures and future. Ann Rheum Dis 2011, 70(Suppl. 1):i64-i66.
2. Theofilopoulos A.N., Gonzalez-Quintial R., Lawson B.R., Koh Y.T., Stern M.E., Kono D.H., et al. Sensors of the innate immune system: their link to rheumatic diseases. Nat Rev Rheumatol 2010, 6:146-156.
3. Kono D.H., Theofilopoulos A.N. Genetics of SLE in mice. Springer Semin Immunopathol 2006, 28:83-96.
4. Zandman-Goddard G., Peeva E., Shoenfeld Y. Gender and autoimmunity. Autoimmun Rev 2007, 6:366-372.
5. Gleicher N., Barad D.H. Gender as risk factor for autoimmune diseases. J Autoimmun 2007, 28:1-6.
6. Lleo A., Battezzati P.M., Selmi C., Gershwin M.E., Podda M. Is autoimmunity a matter of sex?. Autoimmun Rev 2008, 7:626-630.
7. Lockshin M.D. Sex ratio and rheumatic disease. Autoimmun Rev 2002, 1:162-167.
8. Whitacre C.C., Reingold S.C., O'Looney P.A. A gender gap in autoimmunity. Science 1999, 283:1277-1278.
9. Ortona E., Margutti P., Matarrese P., Franconi F., Malorni W. Redox state, cell death and autoimmune diseases: a gender perspective. Autoimmun Rev 2008, 7:579-584.
10. Rubtsov A.V., Rubtsova K., Kappler J.W., Marrack P. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev 2010, 9:494-498.
11. Pollard K.M., Hultman P., Kono D.H. Toxicology of autoimmune diseases. Chem Res Toxicol 2010, 23:455-466.
12. Jayapal M., Bhattacharjee R.N., Melendez A.J., Hande M.P. Environmental toxicogenomics: a post-genomic approach to analysing biological responses to environmental toxins. Int J Biochem Cell Biol 2010, 42:230-240.
13. Rubin R.L. Drug-induced lupus. Toxicology 2005, 209:135-147.
14. Gualtierotti R., Biggioggero M., Penatti A.E., Meroni P.L. Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 2010, 10:3-7.
15. McCombe P.A., Greer J.M., Mackay I.R. Sexual dimorphism in autoimmune disease. Curr Mol Med 2009, 9:1058-1079.
16. Jacobson D.L., Gange S.J., Rose N.R., Graham N.M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997, 84:223-243.
17. Cooper G.S., Bynum M.L., Somers E.C. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009, 33:197-207.
18. Eaton W.W., Rose N.R., Kalaydjian A., Pedersen M.G., Mortensen P.B. Epidemiology of autoimmune diseases in Denmark. J Autoimmun 2007, 29:1-9.
19. Whitacre C.C. Sex differences in autoimmune disease. Nat Immunol 2001, 2:777-780.
20. Chang C., Gershwin M.E. Drugs and autoimmunity-a contemporary review and mechanistic approach. J Autoimmun 2010, 34:J266-J275.
21. Katz U., Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev 2010, 10:46-50.
22. Totoritis M.C., Tan E.M., McNally E.M., Rubin R.L. Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus. N Engl J Med 1988, 318:1431-1436.
23. Cameron H.A., Ramsay L.E. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br Med J (Clin Res Ed) 1984, 289:410-412.
24. Batchelor J.R., Welsh K.I., Tinoco R.M., Dollery C.T., Hughes G.R., Bernstein R., et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1980, 1:1107-1109.
25. Schoonen W.M., Thomas S.L., Somers E.C., Smeeth L., Kim J., Evans S., et al. Do selected drugs increase the risk of lupus? A matched case-control study. Br J Clin Pharmacol 2010, 70:588-596.
26. Bramwell B. Diffuse scleroderma: its frequency, its occurrence in stone masons, its treatment by fibrinolysin injections, elevations of temperature due to fibrinolysin. Edinb J Med 1914, 12:387-401.
27. Thomas C.R., Kelley T.R. A brief review of silicosis in the United States. Environ Health Insights 2010, 4:21-26.
28. Cooper G.S., Wither J., Bernatsky S., Claudio J.O., Clarke A., Rioux J.D., et al. Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology (Oxford) 2010, 49:2172-2180.
29. Finckh A., Cooper G.S., Chibnik L.B., Costenbader K.H., Watts J., Pankey H., et al. Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women. Arthritis Rheum 2006, 54:3648-3654.
30. Parks C.G., Cooper G.S., Nylander-French L.A., Sanderson W.T., Dement J.M., Cohen P.L., et al. Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States. Arthritis Rheum 2002, 46:1840-1850.
31. Masson C., Audran M., Pascaretti C., Chevailler A., Subra J.F., Tuchais E., et al. Silica-associated systemic erythematosus lupus or mineral dust lupus?. Lupus 1997, 6:1-3.
32. Conrad K., Mehlhorn J. Diagnostic and prognostic relevance of autoantibodies in uranium miners. Int Arch Allergy Immunol 2000, 123:77-91.
33. Conrad K., Mehlhorn J., Luthke K., Dorner T., Frank K.H. Systemic lupus erythematosus after heavy exposure to quartz dust in uranium mines: clinical and serological characteristics. Lupus 1996, 5:62-69.
34. McCormic Z.D., Khuder S.S., Aryal B.K., Ames A.L., Khuder S.A. Occupational silica exposure as a risk factor for scleroderma: a meta-analysis. Int Arch Occup Environ Health 2010, 83:763-769.
35. Khuder S.A., Peshimam A.Z., Agraharam S. Environmental risk factors for rheumatoid arthritis. Rev Environ Health 2002, 17:307-315.
36. Gardner R.M., Nyland J.F., Silva I.A., Ventura A.M., de Souza J.M., Silbergeld E.K. Mercury exposure, serum antinuclear/antinucleolar antibodies, and serum cytokine levels in mining populations in Amazonian Brazil: a cross-sectional study. Environ Res 2010, 110:345-354.
37. Silva I.A., Nyland J.F., Gorman A., Perisse A., Ventura A.M., Santos E.C., et al. Mercury exposure, malaria, and serum antinuclear/antinucleolar antibodies in Amazon populations in Brazil: a cross-sectional study. Environ Health 2004, 3:11.
38. Spiegel S.J. Occupational health, mercury exposure, and environmental justice: learning from experiences in Tanzania. Am J Public Health 2009, 99(Suppl. 3):S550-S558.
39. Spiegel S.J., Yassi A., Spiegel J.M., Veiga M.M. Reducing mercury and responding to the global gold rush. Lancet 2005, 366:2070-2072.
40. Veiga M.M., Maxson P.A., Hylander L.D. Origin and consumption of mercury in small-scale mining. J Cleaner Production 2006, 14:436-447.
41. Shen L., Gunson A.J. The role of artisanal and smal-scale mining in China's economy. J Cleaner Production 2006, 14:427-435.
42. Takeuchi K., Turley S.J., Tan E.M., Pollard K.M. Analysis of the autoantibody response to fibrillarin in human disease and murine models of autoimmunity. J Immunol 1995, 154:961-971.
43. Li S.J., Zhang S.H., Chen H.P., Zeng C.H., Zheng C.X., Li L.S., et al. Mercury-induced membranous nephropathy: clinical and pathological features. Clin J Am Soc Nephrol 2010, 5:439-444.
44. Pollard K.M., Hultman P. Skin-lightening creams are a possible exposure risk for systemic lupus erythematosus: comment on the article by Finckh et al. Arthritis Rheum 2007, 56:1721.
45. Weldon M.M., Smolinski M.S., Maroufi A., Hasty B.W., Gilliss D.L., Boulanger L.L., et al. Mercury poisoning associated with a Mexican beauty cream. West J Med 2000, 173:15-18.
46. McKelvey W., Jeffery N., Clark N., Kass D., Parsons P.J. Population-based inorganic mercury biomonitoring and the identification of skin care products as a source of exposure in New York city. Environ Health Perspect 2011, 119:203-209.
47. Sobel E.S., Gianini J., Butfiloski E.J., Croker B.P., Schiffenbauer J., Roberts S.M. Acceleration of autoimmunity by organochlorine pesticides in (NZB × NZW)F1 mice. Environ Health Perspect 2005, 113:323-328.
48. Rosenberg A.M., Semchuk K.M., McDuffie H.H., Ledingham D.L., Cordeiro D.M., Cessna A.J., et al. Prevalence of antinuclear antibodies in a rural population. J Toxicol Environ Health A 1999, 57:225-236.
49. Semchuk K.M., Rosenberg A.M., McDuffie H.H., Cessna A.J., Pahwa P., Irvine D.G. Antinuclear antibodies and bromoxynil exposure in a rural sample. J Toxicol Environ Health A 2007, 70:638-657.
50. Parks C.G., Walitt B.T., Pettinger M., Chen J.C., de Roos A.J., Hunt J., et al. Insecticide use and risk of rheumatoid arthritis and systemic lupus erythematosus in the women's health initiative observational study. Arthritis Care Res (Hoboken) 2011, 63:184-194.
51. Ikeda M. Public health problems of organic solvents. Toxicol Lett 1992, 191-201. 64-65 Spec No.
52. Brautbar N., Williams J. Industrial solvents and liver toxicity: risk assessment, risk factors and mechanisms. Int Journal Hygiene Environmental Health 2002, 205:479-491.
53. Jacob S., Hery M., Protois J.C., Rossert J., Stengel B. Effect of organic solvent exposure on chronic kidney disease progression: the GN-PROGRESS cohort study. J Am Soc Nephrol 2007, 18:274-281.
54. Schenker M.B., Jacobs J.A. Respiratory effects of organic solvent exposure. Tubercle and Lung Disease: Official Journal Int Union Against Tuberculosis Lung Dis 1996, 77:4-18.
55. Brasington R.D., Thorpe-Swenson A.J. Systemic sclerosis associated with cutaneous exposure to solvent: case report and review of the literature. Arthritis Rheum 1991, 34:631-633.
56. Ranque B., Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010, 9:A311-A318.
57. Aryal B.K., Khuder S.A., Schaub E.A. Meta-analysis of systemic sclerosis and exposure to solvents. Am J Ind Med 2001, 40:271-274.
58. Kettaneh A., Al Moufti O., Tiev K.P., Chayet C., Toledano C., Fabre B., et al. Occupational exposure to solvents and gender-related risk of systemic sclerosis: a meta analysis of case-control studies. J Rheumatol 2007, 34:97-103.
59. Cooper G.S., Makris S.L., Nietert P.J., Jinot J. Evidence of autoimmune-related effects of trichloroethylene exposure from studies in mice and humans. Environ Health Perspect 2009, 117:696-702.
60. Mucha L., Stephenson J., Morandi N., Dirani R. Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking. Gend Medicine 2006, 3:279-291.
61. Costenbader K.H., Karlson E.W. Cigarette smoking and autoimmune disease: what can we learn from epidemiology?. Lupus 2006, 15:737-745.
62. Karlson E.W., Lee I.M., Cook N.R., Manson J.E., Buring J.E., Hennekens C.H. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum 1999, 42:910-917.
63. Masdottir B., Jonsson T., Manfredsdottir V., Vikingsson A., Brekkan A., Valdimarsson H. Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:1202-1205.
64. Costenbader K.H., Feskanich D., Mandl L.A., Karlson E.W. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med 2006, 119(503):e1-e9.
65. Gershwin M.E., Selmi C., Worman H.J., Gold E.B., Watnik M., Utts J., et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005, 42:1194-1202.
66. Vestergaard P. Smoking and thyroid disorders-a meta-analysis. Eur journal endocrinology/Eur Fed Endocr Societies 2002, 146:153-161.
67. Olsson A.R., Skogh T., Wingren G. Occupational determinants for rheumatoid arthritis. Scand J Work Environ Health 2000, 26:243-249.
68. de Carvalho J.F., Pereira R.M., Shoenfeld Y. The mosaic of autoimmunity: the role of environmental factors. Front Biosci (Elite Ed) 2009, 1:501-509.
69. Amital H., Govoni M., Maya R., Meroni P.L., Ori B., Shoenfeld Y., et al. Role of infectious agents in systemic rheumatic diseases. Clin Exp Rheumatol 2008, 26:S27-S32.
70. James J.A., Harley J.B., Scofield R.H. Role of viruses in systemic lupus erythematosus and Sjogren syndrome. Curr Opin Rheumatol 2001, 13:370-376.
71. James J.A., Neas B.R., Moser K.L., Hall T., Bruner G.R., Sestak A.L., et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001, 44:1122-1126.
72. Yu S.F., Wu H.C., Tsai W.C., Yen J.H., Chiang W., Yuo C.Y., et al. Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with systemic lupus erythematosus in Taiwan. Med microbiology Immunology 2005, 194:115-120.
73. Ascherio A., Munger K.L. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: Epstein-Barr virus and multiple sclerosis: epidemiological evidence. Clin Exp Immunol 2010, 160:120-124.
74. Shulman L.E. The eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan. Arthritis Rheum 1990, 33:913-917.
75. Okada S., Kamb M.L., Pandey J.P., Philen R.M., Love L.A., Miller F.W. Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms. Arthritis Rheum 2009, 61:1305-1311.
76. Swygert L.A., Maes E.F., Sewell L.E., Miller L., Falk H., Kilbourne E.M. Eosinophilia-myalgia syndrome. Results of national surveillance. Jama 1990, 264:1698-1703.
77. Carr L., Ruther E., Berg P.A., Lehnert H. Eosinophilia-myalgia syndrome in Germany: an epidemiologic review. Mayo Clin Proc 1994, 69:620-625.
78. Kamb M.L., Murphy J.J., Jones J.L., Caston J.C., Nederlof K., Horney L.F., et al. Eosinophilia-myalgia syndrome in L-tryptophan-exposed patients. Jama 1992, 267:77-82.
79. Pestana A., Munoz E. Anilides and the Spanish toxic oil syndrome. Nature 1982, 298:608.
80. Sanchez-Porro Valades P., Posada de la Paz M., de Andres Copa P., Gimenez Ribota O., Abaitua Borda I. Toxic oil syndrome: survival in the whole cohort between 1981 and 1995. J Clin Epidemiol 2003, 56:701-708.
81. Gomez de la Camara A., Posada de la Paz M., Abaitua Borda I., Barainca Oyague M.T., Abraira Santos V., Ruiz-Navarro M.D., et al. Health status measurement in toxic oil syndrome. J Clin Epidemiol 1998, 51:867-873.
82. Troncone R., Jabri B. Coeliac disease and gluten sensitivity. J Intern Med 2011, 269:582-590.
83. Ciacci C., Cirillo M., Sollazzo R., Savino G., Sabbatini F., Mazzacca G. Gender and clinical presentation in adult celiac disease. Scand J Gastroenterol 1995, 30:1077-1081.
84. Murray J.A., Van Dyke C., Plevak M.F., Dierkhising R.A., Zinsmeister A.R., Melton L.J. Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol 2003, 1:19-27.
85. Ivarsson A., Persson L.A., Nystrom L., Hernell O. The Swedish coeliac disease epidemic with a prevailing twofold higher risk in girls compared to boys may reflect gender specific risk factors. Eur journal Epidemiology 2003, 18:677-684.
86. Ivarsson A. The Swedish epidemic of coeliac disease explored using an epidemiological approach-some lessons to be learnt. Best Practice research Clin Gastroenterology 2005, 19:425-440.
87. Hancock S.L., Cox R.S., McDougall I.R. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med 1991, 325:599-605.
88. Eheman C.R., Garbe P., Tuttle R.M. Autoimmune thyroid disease associated with environmental thyroidal irradiation. Thyroid 2003, 13:453-464.
89. Davis S., Kopecky K.J., Hamilton T.E., Onstad L. Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the hanford nuclear site. Jama 2004, 292:2600-2613.
90. Tronko M.D., Brenner A.V., Olijnyk V.A., Robbins J., Epstein O.V., McConnell R.J., et al. Autoimmune thyroiditis and exposure to iodine 131 in the Ukrainian cohort study of thyroid cancer and other thyroid diseases after the chornobyl accident: results from the first screening cycle. J Clin Endocrinol Metab 1998-2000, 2006(91):4344-4351.
91. Taylor B.V. The major cause of multiple sclerosis is environmental: genetics has a minor role - yes. Mult Scler 2011, 17:1171-1173.
92. Simpson S., Blizzard L., Otahal P., Van der Mei I., Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 2011, 82:1132-1141.
93. Taylor B.V., Pearson J.F., Clarke G., Mason D.F., Abernethy D.A., Willoughby E., et al. MS prevalence in New Zealand, an ethnically and latitudinally diverse country. Mult Scler 2010, 16:1422-1431.
94. Orton S.M., Herrera B.M., Yee I.M., Valdar W., Ramagopalan S.V., Sadovnick A.D., et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006, 5:932-936.
95. van der Mei I.A., Ponsonby A.L., Blizzard L., Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 2001, 20:168-174.
96. Danchenko N., Satia J.A., Anthony M.S. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006, 15:308-318.
97. Andrews B.S., Eisenberg R.A., Theofilopoulos A.N., Izui S., Wilson C.B., McConahey P.J., et al. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 1978, 148:1198-1215.
98. Dumont F., Monier J.C. Sex-dependent systemic lupus erythematosus-like syndrome in (NZB × SJL)F1 mice. Clin Immunol Immunopathol 1983, 29:306-317.
99. Vidal S., Gelpi C., Rodriguez-Sanchez J.L. (SWR × SJL)F1 mice: a new model of lupus-like disease. J Exp Med 1994, 179:1429-1435.
100. Roubinian J.R., Talal N., Greenspan J.S., Goodman J.R., Siiteri P.K. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med 1978, 147:1568-1583.
101. Rudofsky U.H., Evans B.D., Balaban S.L., Mottironi V.D., Gabrielsen A.E. Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization. Lab Invest 1993, 68:419-426.
102. Hudson C.A., Cao L., Kasten-Jolly J., Kirkwood J.N., Lawrence D.A. Susceptibility of lupus-prone NZM mouse strains to lead exacerbation of systemic lupus erythematosus symptoms. J Toxicol Environ Health A 2003, 66:895-918.
103. Mitchell D.A., Pickering M.C., Warren J., Fossati-Jimack L., Cortes-Hernandez J., Cook H.T., et al. C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol 2002, 168:2538-2543.
104. Izui S., Merino R., Fossati L., Iwamoto M. The role of the Yaa gene in lupus syndrome. Int Rev Immunol 1994, 11:211-230.
105. Pisitkun P., Deane J.A., Difilippantonio M.J., Tarasenko T., Satterthwaite A.B., Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006, 312:1669-1672.
106. Rubtsov A.V., Rubtsova K., Fischer A., Meehan R.T., Gillis J.Z., Kappler J.W., et al. Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c B-cell population is important for the development of autoimmunity. Blood 2011, 118:1305-1315.
107. Meier A., Chang J.J., Chan E.S., Pollard R.B., Sidhu H.K., Kulkarni S., et al. Sex differences in the toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009, 15:955-959.
108. Baccala R., Hoebe K., Kono D.H., Beutler B., Theofilopoulos A.N. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007, 13:543-551.
109. Hu W., Ren H. A meta-analysis of the association of IRF5 polymorphism with systemic lupus erythematosus. Int J Immunogenet 2011, 38:411-417.
110. Shen H., Panchanathan R., Rajavelu P., Duan X., Gould K.A., Choubey D. Gender-dependent expression of murine Irf5 gene: implications for sex bias in autoimmunity. J Mol Cell Biol 2010, 2:284-290.
111. von Herrath M., Nepom G.T. Animal models of human type 1 diabetes. Nat Immunol 2009, 10:129-132.
112. Bao M., Yang Y., Jun H.S., Yoon J.W. Molecular mechanisms for gender differences in susceptibility to T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol 2002, 168:5369-5375.
113. Voskuhl R. Sex differences in autoimmune diseases. Biol Sex Differences 2011, 2:1. 10.1186/2042-6410-2-1.
114. Brown J.M., Archer A.J., Pfau J.C., Holian A. Silica accelerated systemic autoimmune disease in lupus-prone New Zealand mixed mice. Clin Exp Immunol 2003, 131:415-421.
115. Pfau J.C., Sentissi J.J., Li S., Calderon-Garciduenas L., Brown J.M., Blake D.J. Asbestos-induced autoimmunity in C57BL/6 mice. J Immunotoxicol 2008, 5:129-137.
116. Schiraldi M., Monestier M. How can a chemical element elicit complex immunopathology? Lessons from mercury-induced autoimmunity. Trends Immunol 2009, 30:502-509.
117. Hultman P., Bell L.J., Enestrom S., Pollard K.M. Murine susceptibility to mercury. II. Autoantibody profiles and renal immune deposits in hybrid, backcross, and H-2d congenic mice. Clin Immunol Immunopathol 1993, 68:9-20.
118. Hultman P., Bell L.J., Enestrom S., Pollard K.M. Murine susceptibility to mercury. I. Autoantibody profiles and systemic immune deposits in inbred, congenic, and intra-H-2 recombinant strains. Clin Immunol Immunopathol 1992, 65:98-109.
119. Hultman P., Enestrom S. Dose-response studies in murine mercury-induced autoimmunity and immune - complex disease. Toxicol Appl Pharmacol 1992, 113:199-208.
120. Hultman P., Nielsen J.B. The effect of dose, gender, and non-H-2 genes in murine mercury-induced autoimmunity. J Autoimmun 2001, 17:27-37.
121. al-Balaghi S., Moller E., Moller G., Abedi-Valugerdi M. Mercury induces polyclonal B cell activation, autoantibody production and renal immune complex deposits in young (NZB × NZW)F1 hybrids. Eur J Immunol 1996, 26:1519-1526.
122. Pollard K.M., Pearson D.L., Hultman P., Hildebrandt B., Kono D.H. Lupus-prone mice as models to study xenobiotic-induced acceleration of systemic autoimmunity. Environ Health Perspect 1999, 107(Suppl. 5):729-735.
123. Havarinasab S., Hultman P. Alteration of the spontaneous systemic autoimmune disease in (NZB × NZW)F1 mice by treatment with thimerosal (ethyl mercury). Toxicol Appl Pharmacol 2006, 214:43-54.
124. Pollard K.M., Pearson D.L., Hultman P., Deane T.N., Lindh U., Kono D.H. Xenobiotic acceleration of idiopathic systemic autoimmunity in lupus - prone bxsb mice. Environ Health Perspect 2001, 109:27-33.
125. Hultman P., Taylor A., Yang J.M., Pollard K.M. The effect of xenobiotic exposure on spontaneous autoimmunity in (SWR × SJL)F1 hybrid mice. J Toxicol Environ Health A 2006, 69:505-523.
126. Brenden N., Rabbani H., Abedi-Valugerdi M. Analysis of mercury-induced immune activation in nonobese diabetic (NOD) mice. Clin Exp Immunol 2001, 125:202-210.
127. Nyland J.F., Fairweather D., Shirley D.L., Davis S.E., Rose N.R., Silbergeld E.K. Low dose inorganic mercury increases severity and frequency of chronic coxsackievirus-induced autoimmune myocarditis in mice. Toxicol Sci 2011, 10.1093/toxsci/kfr264.
128. Reeves W.H., Lee P.Y., Weinstein J.S., Satoh M., Lu L. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol 2009, 30:455-464.
129. Satoh M., Richards H.B., Shaheen V.M., Yoshida H., Shaw M., Naim J.O., et al. Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. Clin Exp Immunol 2000, 121:399-405.
130. Smith D.L., Dong X., Du S., Oh M., Singh R.R., Voskuhl R.R. A female preponderance for chemically induced lupus in SJL/J mice. Clin Immunol 2007, 122:101-107.
131. Smith-Bouvier D.L., Divekar A.A., Sasidhar M., Du S., Tiwari-Woodruff S.K., King J.K., et al. A role for sex chromosome complement in the female bias in autoimmune disease. J Exp Med 2008, 205:1099-1108.
132. Schecter A., Birnbaum L., Ryan J.J., Constable J.D. Dioxins: an overview. Environ Res 2006, 101:419-428.
133. Kerkvliet N.I., Steppan L.B., Vorachek W., Oda S., Farrer D., Wong C.P., et al. Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. Immunotherapy 2009, 1:539-547.
134. Li J., McMurray R.W. Effects of chronic exposure to DDT and TCDD on disease activity in murine systemic lupus erythematosus. Lupus 2009, 18:941-949.
135. Quintana F.J., Basso A.S., Iglesias A.H., Korn T., Farez M.F., Bettelli E., et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008, 453:65-71.
136. Mustafa A., Holladay S.D., Witonsky S., Sponenberg D.P., Karpuzoglu E., Gogal R.M. A single mid-gestation exposure to TCDD yields a postnatal autoimmune signature, differing by sex, in early geriatric C57BL/6 mice. Toxicology 2011, 10.1016/j.tox.2011.08.021.
137. Holladay S.D., Mustafa A., Gogal R.M. Prenatal TCDD in mice increases adult autoimmunity. Reprod Toxicol 2011, 31:312-318.
138. Sobel E.S., Wang F., Butfiloski E., Croker B., Roberts S.M. Comparison of chlordecone effects on autoimmunity in (NZB × NZW) F(1) and BALB/c mice. Toxicology 2006, 218:81-89.
139. Wang F., Roberts S.M., Butfiloski E.J., Sobel E.S. Diminished prolactin from chlordecone treatment in ovariectomized (NZB × NZW)F(1) mice. Int Immunopharmacol 2007, 7:1808-1812.
140. Pachner A.R. Experimental models of multiple sclerosis. Curr opinion Neurology 2011, 24:291-299.
141. Oleszak E.L., Chang J.R., Friedman H., Katsetos C.D., Platsoucas C.D. Theiler's virus infection: a model for multiple sclerosis. Clin Microbiol Rev 2004, 17:174-207.
142. Lipton H.L., Dal Canto M.C. Susceptibility of inbred mice to chronic central nervous system infection by Theiler's murine encephalomyelitis virus. Infect Immun 1979, 26:369-374.
143. Alley J., Khasabov S., Simone D., Beitz A., Rodriguez M., Njenga M.K. More severe neurologic deficits in SJL/J male than female mice following Theiler's virus-induced CNS demyelination. Exp Neurol 2003, 180:14-24.
144. Lipton H.L. Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination. Infect Immun 1975, 11:1147-1155.
145. Hill K.E., Pigmans M., Fujinami R.S., Rose J.W. Gender variations in early Theiler's virus induced demyelinating disease: differential susceptibility and effects of IL-4, IL-10 and combined IL-4 with IL-10. J Neuroimmunol 1998, 85:44-51.
146. Mohindru M., Kang B., Kim B.S. Initial capsid-specific CD4(+) T cell responses protect against Theiler's murine encephalomyelitisvirus-induced demyelinating disease. Eur J Immunol 2006, 36:2106-2115.
147. Cihakova D., Rose N.R. Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol 2008, 99:95-114.
148. Gauntt C.J., Gomez P.T., Duffey P.S., Grant J.A., Trent D.W., Witherspoon S.M., et al. Characterization and myocarditic capabilities of coxsackievirus B3 variants in selected mouse strains. J Virol 1984, 52:598-605.
149. Wolfgram L.J., Beisel K.W., Herskowitz A., Rose N.R. Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice. J Immunol 1986, 136:1846-1852.
150. Huber S.A. Increased susceptibility of male BALB/c mice to coxsackievirus B3-induced myocarditis: role for CD1d. Med microbiology Immunology 2005, 194:121-127.
151. Lyden D.C., Olszewski J., Feran M., Job L.P., Huber S.A. Coxsackievirus B-3-induced myocarditis. Effect of sex steroids on viremia and infectivity of cardiocytes. Am J Pathol 1987, 126:432-438.
152. Frisancho-Kiss S., Nyland J.F., Davis S.E., Frisancho J.A., Barrett M.A., Rose N.R., et al. Sex differences in coxsackievirus B3-induced myocarditis: IL-12Rbeta1 signaling and IFN-gamma increase inflammation in males independent from STAT4. Brain Res 2006, 1126:139-147.
153. Frisancho-Kiss S., Davis S.E., Nyland J.F., Frisancho J.A., Cihakova D., Barrett M.A., et al. Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol 2007, 178:6710-6714.
154. Frisancho-Kiss S., Coronado M.J., Frisancho J.A., Lau V.M., Rose N.R., Klein S.L., et al. Gonadectomy of male BALB/c mice increases Tim-3(+) alternatively activated M2 macrophages, Tim-3(+) T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis. Brain Behav Immun 2009, 23:649-657.
155. Piccio L., Stark J.L., Cross A.H. Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis. J Leukoc Biol 2008, 84:940-948.
156. Esquifino A.I., Cano P., Jimenez V., Cutrera R.A., Cardinali D.P. Experimental allergic encephalomyelitis in male Lewis rats subjected to calorie restriction. J Physiol Biochem 2004, 60:245-252.
157. Esquifino A.I., Cano P., Jimenez-Ortega V., Fernandez-Mateos M.P., Cardinali D.P. Immune response after experimental allergic encephalomyelitis in rats subjected to calorie restriction. J Neuroinflammation 2007, 4:6. 10.1186/1742-2094-4-6.
158. Chandrasekar B., McGuff H.S., Aufdermorte T.B., Troyer D.A., Talal N., Fernandes G. Effects of calorie restriction on transforming growth factor beta 1 and proinflammatory cytokines in murine Sjogren's syndrome. Clin Immunol Immunopathol 1995, 76:291-296.
159. Sun D., Krishnan A., Su J., Lawrence R., Zaman K., Fernandes G. Regulation of immune function by calorie restriction and cyclophosphamide treatment in lupus-prone NZB/NZW F1 mice. Cell Immunol 2004, 228:54-65.
160. Sogawa H., Kubo C. Influence of short-term repeated fasting on the longevity of female (NZB × NZW)F1 mice. Mech Ageing Dev 2000, 115:61-71.
161. Abe T., Nakajima A., Satoh N., Ohkoshi M., Sakuragi S., Koizumi A. Suppression of experimental autoimmune uveoretinitis by dietary calorie restriction. Jpn J Ophthalmol 2001, 45:46-52.
162. Morgan T.E., Wong A.M., Finch C.E. Anti-inflammatory mechanisms of dietary restriction in slowing aging processes. Interdiscip topics Gerontology 2007, 35:83-97.
163. Ansel J.C., Mountz J., Steinberg A.D., DeFabo E., Green I. Effects of UV radiation on autoimmune strains of mice: increased mortality and accelerated autoimmunity in BXSB male mice. J Invest Dermatol 1985, 85:181-186.
164. McGrath H., Bak E., Michalski J.P. Ultraviolet-A light prolongs survival and improves immune function in (New Zealand black × New Zealand white)F1 hybrid mice. Arthritis Rheum 1987, 30:557-561.
165. Xue D., Shi H., Smith J.D., Chen X., Noe D.A., Cedervall T., et al. A lupus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen. Proc Natl Acad Sci U S A 2003, 100:7503-7508.